MedTrace Logo

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

NCT07030712 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2026-03-16

No results posted yet for this study

Summary

MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.

Conditions

  • Metastatic Neoplasm

Interventions

DRUG

MK-8294

30 µg via intravenous (IV) infusion

DRUG

MK-8294

100 µg via intravenous (IV) infusion

DRUG

MK-8294

300 µg via intravenous (IV) infusion

DRUG

MK-8294

1 mg via intravenous (IV) infusion

DRUG

MK-8294

3 mg via intravenous (IV) infusion

DRUG

MK-8294

10 mg via intravenous (IV) infusion

DRUG

MK-8294

30 mg via intravenous (IV) infusion

DRUG

MK-8294

70 mg via intravenous (IV) infusion

OTHER

CD8 PET Tracer

IV Infusion

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-23
Primary Completion
2027-08-23
Completion
2027-08-23
FDA Drug
Yes

Countries

  • United States
  • Israel
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07030712 on ClinicalTrials.gov